General information

Announcements(0)

Greetings from the Chair

Overview

Web abstract

Registration

Information for Speakers, Presenters and Chairs

Program

Sessions

Search presentations

General information 2

Abstract Submission (Oral/Poster Presentation)

pharm143_en.png

icon_20251203182619268.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

Enter the password to view the abstracts. The password will be emailed to those who have completed the registration.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Announcements

Profile management

Bookmark

Download PDF for print

Timetable

Application of human iPS cells-derived cardiac and neural cells for safety assessment and expectations for MPS implementation

Microphysiological systems (MPS) are generally known as advanced in vitro culture systems using single or multiple types of cells in an in vivo mimetic manner, and they are expected to provide significant beneficial impacts on drug discovery, such as improvement of data extrapolability to humans and reduction of animal use. To accelerate MPS developments for their implementation into drug development studies, we need to build concrete consensus on their usability, quality and applicability through deeper communication among all stakeholders. With these background in mind, this symposium aims to creating consensus views and future milestones on development and use of MPS in drug development studies. To these ends, Dr. Furihata will talk about an industry-academia collaboration work for development of human blood-brain barrier MPS, and Dr. Kojima will present a unique technology enabling to produce customizable spheroids-on-demand. Dr. Yamamoto will introduce a new type of a lung MPS based on a unique iPS differentiation technique to respiratory cells. Furthermore, Dr, Taniguchi will summarize the current status and perspectives on cell-based methods, including MPS, in non-clinical safety pharmacology studies. Finally, Dr. Okubo will show the practical impacts of automation technology on MPS-based assay systems in pharmaceutical companies. Through these talks, we would like to draw a future path toward the implementation of MPS in drug discovery research.

Microphysiological systems: Current understanding and perspectives in drug development studies

The 143rd Annual Meeting of the Pharmaceutical Society of Japan (Sapporo)

Presentation Information

[S03-04]Application of human iPS cells-derived cardiac and neural cells for safety assessment and expectations for MPS implementation

Password required to view